Ortho-McNeil Pharma Licenses Additional Component of Cellzome s Alzheimer Program | GenomeWeb

NEW YORK, May 23 (GenomeWeb News) - Ortho-McNeil Pharmaceutical has licensed another part of Cellzome's proteomics-based Alzheimer's disease program, exercising an option under the terms of a collaboration signed between the two companies in March, Cellzome said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.